Exogene utilizes a generative AI platform to mine the T-cell receptor (TCR) sequence space for novel, high-affinity TCRs. This technology addresses the difficulty of identifying effective TCRs against cancer targets using traditional discovery methods. The company aims to unlock curative TCR-based immunotherapies for solid tumor eradication.
Funding
$2.1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
EFJGSV+1Founders
Product
Problem
Identifying safe and effective T-cell receptors (TCRs) for solid tumor immunotherapy is challenging due to the rarity of high-affinity, non-cross-reactive TCRs and the limitations of traditional wet-lab methods. This bottleneck hinders the development of TCR-based therapies that can effectively target diverse cancer types and patient populations.
Solution
Exogene leverages a generative AI platform to accelerate the discovery of novel, high-affinity, and non-cross-reactive TCRs for targeting solid tumors. The platform comprehensively mines the TCR sequence space, combining generative AI for TCR generation with biophysical simulations to refine TCRs in silico. High-throughput TCR display technologies and biophysical assays are then used to experimentally validate the AI-generated TCRs. This integrated approach aims to overcome the scalability limitations of traditional methods, enabling the rapid identification of therapeutically relevant TCRs for cancer immunotherapy.
Target Audience
Exogene's primary customers are pharmaceutical and biotechnology companies focused on developing TCR-based immunotherapies for solid tumors.
Features
- Generative AI platform for de novo TCR sequence design and optimization
- In silico biophysical simulations to predict TCR affinity and specificity
- High-throughput screening assays for experimental validation of AI-designed TCRs
- Identification of TCRs against targets shared across patients and tumor types
- TCR affinity enhancement technology to improve therapeutic activity
- Collaboration with Immunocore to engineer T-cell receptors using artificial intelligence